A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.

NCT00365131 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Gaucher Disease Type I
Cerebroside Lipidosis Syndrome
Clucocerebrosidase Deficiency Disease
Glucosylceramide Beta-Glucosidase Deficiency Disease
Gaucher Disease, Non-Neuronopathic Form

Interventions

DRUG: Cerezyme (imiglucerase for injection)

Sponsor

Genzyme, a Sanofi Company